Clearside Biomedical, Inc. (CLSD) announced plans to explore a full range of strategic alternatives to advance its SCS platform and drug development pipeline to maximize stockholder value. The company has retained Piper Sandler to support it with the strategic evaluation process. The company noted that the strategic alternatives under consideration include the sale, license, monetization and/or divestiture of one or more of the company's assets and technologies, collaboration, partnership, merger, acquisition, joint ventures, or other strategic transactions.
"In order to facilitate this process and conserve cash, while continuing our support of the company's SCS Microinjector licensees, all Clearside employees, including the Chief Executive Officer, Chief Financial Officer, and Chief Medical Officer, will transition into consulting roles with the company this week. In addition, we will pause all internal research and development programs during this process," said George Lasezkay, President and CEO.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.